584 related articles for article (PubMed ID: 29720240)
1. Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus.
Cole S; Walsh A; Yin X; Wechalekar MD; Smith MD; Proudman SM; Veale DJ; Fearon U; Pitzalis C; Humby F; Bombardieri M; Axel A; Adams H; Chiu C; Sharp M; Alvarez J; Anderson I; Madakamutil L; Nagpal S; Guo Y
Arthritis Res Ther; 2018 May; 20(1):85. PubMed ID: 29720240
[TBL] [Abstract][Full Text] [Related]
2. CD38 and E2F transcription factor 2 have uniquely increased expression in rheumatoid arthritis synovial tissues.
Chang X; Yue L; Liu W; Wang Y; Wang L; Xu B; Wang Y; Pan J; Yan X
Clin Exp Immunol; 2014 May; 176(2):222-31. PubMed ID: 24397353
[TBL] [Abstract][Full Text] [Related]
3. Potential therapeutic effects of cyanidin-3-O-glucoside on rheumatoid arthritis by relieving inhibition of CD38+ NK cells on Treg cell differentiation.
Wang H; Li S; Zhang G; Wu H; Chang X
Arthritis Res Ther; 2019 Oct; 21(1):220. PubMed ID: 31661005
[TBL] [Abstract][Full Text] [Related]
4. The NADase enzyme CD38: an emerging pharmacological target for systemic sclerosis, systemic lupus erythematosus and rheumatoid arthritis.
Peclat TR; Shi B; Varga J; Chini EN
Curr Opin Rheumatol; 2020 Nov; 32(6):488-496. PubMed ID: 32941246
[TBL] [Abstract][Full Text] [Related]
5. Biosemantics guided gene expression profiling of Sjögren's syndrome: a comparative analysis with systemic lupus erythematosus and rheumatoid arthritis.
Shah NR; Noll BD; Stevens CB; Brennan MT; Mougeot FB; Mougeot JC
Arthritis Res Ther; 2017 Aug; 19(1):192. PubMed ID: 28818099
[TBL] [Abstract][Full Text] [Related]
6. Dysregulated CD38 Expression on Peripheral Blood Immune Cell Subsets in SLE.
Burns M; Ostendorf L; Biesen R; Grützkau A; Hiepe F; Mei HE; Alexander T
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33670902
[TBL] [Abstract][Full Text] [Related]
7. Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus.
Nzeusseu Toukap A; Galant C; Theate I; Maudoux AL; Lories RJ; Houssiau FA; Lauwerys BR
Arthritis Rheum; 2007 May; 56(5):1579-88. PubMed ID: 17469140
[TBL] [Abstract][Full Text] [Related]
8. miR-210 expression in PBMCs from patients with systemic lupus erythematosus and rheumatoid arthritis.
Huang Q; Chen SS; Li J; Tao SS; Wang M; Leng RX; Pan HF; Ye DQ
Ir J Med Sci; 2018 Feb; 187(1):243-249. PubMed ID: 28560518
[TBL] [Abstract][Full Text] [Related]
9. Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus.
Ostendorf L; Burns M; Durek P; Heinz GA; Heinrich F; Garantziotis P; Enghard P; Richter U; Biesen R; Schneider U; Knebel F; Burmester G; Radbruch A; Mei HE; Mashreghi MF; Hiepe F; Alexander T
N Engl J Med; 2020 Sep; 383(12):1149-1155. PubMed ID: 32937047
[TBL] [Abstract][Full Text] [Related]
10. Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis.
Kruithof E; Baeten D; De Rycke L; Vandooren B; Foell D; Roth J; Cañete JD; Boots AM; Veys EM; De Keyser F
Arthritis Res Ther; 2005; 7(3):R569-80. PubMed ID: 15899044
[TBL] [Abstract][Full Text] [Related]
11. Restoration of NK Cell Cytotoxic Function With Elotuzumab and Daratumumab Promotes Elimination of Circulating Plasma Cells in Patients With SLE.
Humbel M; Bellanger F; Fluder N; Horisberger A; Suffiotti M; Fenwick C; Ribi C; Comte D
Front Immunol; 2021; 12():645478. PubMed ID: 33828555
[TBL] [Abstract][Full Text] [Related]
12. PD-L1
Zacca ER; Onofrio LI; Acosta CDV; Ferrero PV; Alonso SM; Ramello MC; Mussano E; Onetti L; Cadile II; Stancich MI; Taboada Bonfanti MC; Montes CL; Acosta Rodríguez EV; Gruppi A
Front Immunol; 2018; 9():2241. PubMed ID: 30327652
[No Abstract] [Full Text] [Related]
13. IRF4 and IRGs Delineate Clinically Relevant Gene Expression Signatures in Systemic Lupus Erythematosus and Rheumatoid Arthritis.
Rodríguez-Carrio J; López P; Alperi-López M; Caminal-Montero L; Ballina-García FJ; Suárez A
Front Immunol; 2018; 9():3085. PubMed ID: 30666255
[No Abstract] [Full Text] [Related]
14. Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus.
Cohen S; Clowse M; Pardo P; Bhattacharya I; Menon S; Gourley I; Diehl A
Clin Ther; 2016 Jun; 38(6):1417-1434.e2. PubMed ID: 27112532
[TBL] [Abstract][Full Text] [Related]
15. Comparative single-cell multiplex immunophenotyping of therapy-naive patients with rheumatoid arthritis, systemic sclerosis, and systemic lupus erythematosus shed light on disease-specific composition of the peripheral immune system.
Balog JÁ; Zvara Á; Bukovinszki V; Puskás LG; Balog A; Szebeni GJ
Front Immunol; 2024; 15():1376933. PubMed ID: 38726007
[TBL] [Abstract][Full Text] [Related]
16. A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis.
Cohen S; Beebe JS; Chindalore V; Guan S; Hassan-Zahraee M; Saxena M; Xi L; Hyde C; Koride S; Levin R; Lubaczewski S; Salganik M; Sloan A; Stevens E; Peeva E; Vincent MS; Martin DA; Chu M
Arthritis Res Ther; 2024 Jun; 26(1):117. PubMed ID: 38845046
[TBL] [Abstract][Full Text] [Related]
17. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.
Vallerskog T; Heimbürger M; Gunnarsson I; Zhou W; Wahren-Herlenius M; Trollmo C; Malmström V
Arthritis Res Ther; 2006; 8(6):R167. PubMed ID: 17092341
[TBL] [Abstract][Full Text] [Related]
18. Novel role of plasmacytoid dendritic cells in humans: induction of interleukin-10-producing Treg cells by plasmacytoid dendritic cells in patients with rheumatoid arthritis responding to therapy.
Kavousanaki M; Makrigiannakis A; Boumpas D; Verginis P
Arthritis Rheum; 2010 Jan; 62(1):53-63. PubMed ID: 20039433
[TBL] [Abstract][Full Text] [Related]
19. Expression of Fcgamma and complement receptors on peripheral blood monocytes in systemic lupus erythematosus and rheumatoid arthritis.
Hepburn AL; Mason JC; Davies KA
Rheumatology (Oxford); 2004 May; 43(5):547-54. PubMed ID: 14747618
[TBL] [Abstract][Full Text] [Related]
20. Triple DMARD treatment in early rheumatoid arthritis modulates synovial T cell activation and plasmablast/plasma cell differentiation pathways.
Walsh AM; Wechalekar MD; Guo Y; Yin X; Weedon H; Proudman SM; Smith MD; Nagpal S
PLoS One; 2017; 12(9):e0183928. PubMed ID: 28863153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
